The novel functions of ubiquitination in signaling

Current Opinion in Cell Biology

Volumn 16, Issue 2, 2004, Pages 119-126

  Sun, Lijun ^a   Chen, Zhijian J ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

deubiquitination enzyme; Dub; FA; Fanconi Anemia; PolyUb; polyubiquitin; TLR; Toll like receptor; Ub; ubiquitin; ubiquitin specific protease; UBP

Indexed keywords

BRCA1 PROTEIN; CD40 ANTIGEN; DNA; FANCONI ANEMIA PROTEIN; I KAPPA B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTYROSINE; PROTEASOME; PROTEIN; PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

CELL LINE; COVALENT BOND; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA STRAND BREAKAGE; DNA SYNTHESIS; DOWN REGULATION; ENZYME ACTIVATION; FANCONI ANEMIA; GENE SILENCING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION;

ANIMALS; DNA REPAIR; HUMANS; I-KAPPA B KINASE; POLYMERS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 2342477917     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ceb.2004.02.005     Document Type: Review

References (44)

1. Johnson E.S. Ubiquitin branches out. Nat Cell Biol. 4:2002;E295-E298
2. Pickart C.M. Ubiquitin enters the new millennium. Mol Cell. 8:2001;499-504
3. Pickart C.M. Mechanisms underlying ubiquitination. Annu Rev Biochem. 70:2001;503-533
4. Pickart C.M. Ubiquitin in chains. Trends Biochem Sci. 25:2000;544-548
5. Wong B.R., Parlati F., Qu K., Demo S., Pray T., Huang J., Payan D.G., Bennett M.K. Drug discovery in the ubiquitin regulatory pathway. Drug Discov Today. 8:2003;746-754
6. Schwartz D.C., Hochstrasser M. A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem Sci. 28:2003;321-328
7. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934
8. Schnell J.D., Hicke L. Non-traditional functions of ubiquitin and ubiquitin-binding proteins. J Biol Chem. 278:2003;35857-35860
9. Ghosh S., Karin M. Missing pieces in the NF-κB puzzle. Cell. 109(Suppl):2002;S81-S96
10. Maniatis T. A ubiquitin ligase complex essential for the NF-κB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev. 13:1999;505-510
11. Palombella V.J., Rando O.J., Goldberg A.L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell. 78:1994;773-785
12. Chen Z.J., Parent L., Maniatis T. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell. 84:1996;853-862
13. Hochstrasser M. Protein degradation or regulation: Ub the judge. Cell. 84:1996;813-815
14. Deng L., Wang C., Spencer E., Yang L., Braun A., You J., Slaughter C., Pickart C., Chen Z.J. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 103:2000;351-361
15. Dunne A., O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE. 2003:2003;re3
16. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 412:2001;346-351
17. Shi C.S., Kehrl J.H. Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2). J Biol Chem. 278:2003;15429-15434 This paper demonstrates that TRAF2 is conjugated by K63-linked polyubiquitin chain following TNF stimulation and that this modification is important for the activation of GCKR and SAPK/JNK. TRAF2 polyubiquitination and the activation of GCKR and SAPK require Ubc13. This study, together with an earlier study demonstrating the role of Ubc13 in TNF- and TRAF2-induced activation of NF-κB [14], provides strong evidence that K63-linked polyubiquitination plays an important role in the TNF pathway.
18. Tang E.D., Wang C.Y., Xiong Y., Guan K.L. A role for NF-κB essential modifier/IκB kinase-γ (NEMO/IKKγ) ubiquitination in the activation of the IκB kinase complex by tumor necrosis factor-α J Biol Chem. 278:2003;37297-37305 This paper provides evidence that NEMO is polyubiquitinated following TNF stimulation and that NEMO ubiquitination is impaired by a C-terminal zinc finger domain mutation found in patients with hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID). Ubiquitination of NEMO is mediated by the RING-domain protein cIAP1 and Ubc5. Ubc5-mediated activation of IKK was also reported in an earlier paper that describes the discovery of the IκB kinase complex and the ubiquitin-dependent activation of this kinase [12].
19. Legler D.F., Micheau O., Doucey M.A., Tschopp J., Bron C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNFα-mediated NF-κB activation. Immunity. 18:2003;655-664
20. Wilkinson K.D. Signal transduction: aspirin, ubiquitin and cancer. Nature. 424:2003;738-739
21. Bignell G.R., Warren W., Seal S., Takahashi M., Rapley E., Barfoot R., Green H., Brown C., Biggs P.J., Lakhani S.R., et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 25:2000;160-165
22. ••], provides strong evidence that the tumor-suppressing function of CYLD is mediated through its ability to function as a deubiquitination enzyme that disassembles K63-linked polyubiquitin chains on TRAF2, TRAF6 and NEMO. Overexpression of CYLD suppresses IKK activation. Conversely, reduction of CYLD expression or mutations of CYLD that abrogate its deubiquitination enzyme activity potentiates IKK activation. CYLD binds to NEMO and may use NEMO as a docking site to gain access to polyubiquitin chains on the TRAF proteins as well as on NEMO.
23. ••].
24. ••].
25. Balakirev M.Y., Tcherniuk S.O., Jaquinod M., Chroboczek J. Otubains: a new family of cysteine proteases in the ubiquitin pathway. EMBO Rep. 4:2003;517-522
26. Orth K., Xu Z., Mudgett M.B., Bao Z.Q., Palmer L.E., Bliska J.B., Mangel W.F., Staskawicz B., Dixon J.E. Disruption of signaling by Yersinia effector YopJ, a ubiquitin-like protein protease. Science. 290:2000;1594-1597
27. Collier-Hyams L.S., Zeng H., Sun J., Tomlinson A.D., Bao Z.Q., Chen H., Madara J.L., Orth K., Neish A.S. Cutting edge: Salmonella AvrA effector inhibits the key proinflammatory, anti-apoptotic NF-κB pathway. J Immunol. 169:2002;2846-2850
28. Huang T.T., Wuerzberger-Davis S.M., Wu Z.H., Miyamoto S. Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell. 115:2003;565-576 This paper presents the remarkable finding that modification of NEMO by SUMO and ubiquitin provides a nuclear signal that transmits the DNA damage information from the nucleus to the cytoplasm. Importantly, the authors identify the sumoylation/ubiquitination sites in NEMO and show that mutations at these sites abolish IKK activation in response to DNA damage. In addition, the authors outline the sequence of events of Nemo modification, and show that sumoylation precedes ATM phosphorylation, which precedes ubiquitination.
29. Hoege C., Pfander B., Moldovan G.L., Pyrowolakis G., Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature. 419:2002;135-141 This paper provides compelling evidence that PCNA is the physiological target of ubiquitination that regulates DNA repair. Most strikingly, a single lysine residue on PCNA undergoes a switch from sumoylation to monoubiquitination to K63-linked polyubiquitination, and each of these modifications gives rise to different outcomes with regard to DNA repair. The identification of PCNA as the major ubiquitination target in DNA repair provides a satisfactory answer to the long-standing mystery of the DNA repair phenotypes of RAD6, RAD18, RAD5 and Ubc13/Mms2.
30. Stelter P., Ulrich H.D. Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation. Nature. 425:2003;188-191 This paper shows that monoubiquitinated PCNA activates translesion DNA synthesis by damage-tolerant DNA polymerases, and is required for damage-induced mutagenesis. In addition, the authors showed that monoubiquitination and sumoylation of PCNA contribute to spontaneous mutagenesis.
31. Ulrich H.D., Jentsch S. Two RING finger proteins mediate cooperation between ubiquitin-conjugating enzymes in DNA repair. EMBO J. 19:2000;3388-3397
32. Spence J., Sadis S., Haas A.L., Finley D. A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol Cell Biol. 15:1995;1265-1273
33. Hofmann R.M., Pickart C.M. Noncanonical MMS2-encoded ubiquitin- conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell. 96:1999;645-653
34. D'Andrea A.D. The Fanconi road to cancer. Genes Dev. 17:2003;1933-1936
35. Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C., Kim S.T., Lane W.S., Kastan M.B., D'Andrea A.D. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell. 109:2002;459-472 This paper shows that the Fanconi anemia protein FANCD2 is phosphorylated in response to ionizing radiation, and monoubiquitinated in response to the cross-linker mitomycin C (MMC). These different post-translational modifications occur independently and regulate distinct signaling outputs.
36. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J., Grompe M., D'Andrea A.D. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 7:2001;249-262 This is the first report that FANCD2 is monoubiquitinated upon DNA damage, and that monoubiquitinated FANCD2 is activated and recruited to the BRCA1 foci.
37. Meetei A.R., de Winter J.P., Medhurst A.L., Wallisch M., Waisfisz Q., van de Vrugt H.J., Oostra A.B., Yan Z., Ling C., Bishop C.E., et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet. 35:2003;165-170 This paper identifies PHF9 as a PHD domain ubiquitin ligase that is required for FANCD2 ubiquitination in vivo. Importantly, the authors also found that PHF9 is deficient in an FA patient, thus demonstrating PHF9 as a bona fide FA protein.
38. Baer R., Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev. 12:2002;86-91
39. Vandenberg C.J., Gergely F., Ong C.Y., Pace P., Mallery D.L., Hiom K., Patel K.J. BRCA1-independent ubiquitination of FANCD2. Mol Cell. 12:2003;247-254
40. Nishikawa H, Ooka S, Sato K, Arima K, Okamoto J, Klevit RE, Fukuda M, Ohta T: Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J Biol Chem 2004, in press.
41. Wu-Baer F., Lagrazon K., Yuan W., Baer R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J Biol Chem. 278:2003;34743-34746
42. Mallery D.L., Vandenberg C.J., Hiom K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J. 21:2002;6755-6762
43. Varadan R, Assfalg M, Haririnia A, Raasi S, Pickart C, Fushman D: Solution conformation of Lys63-linked di-ubiqutin chain provides clues to functional diversity of polyubiquitin signaling. J Biol Chem 2004, in press.
44. Zhou H, Wertz I, O'Rourke K, Ultsch M, Seshagiri S, Eby M, Xiao W, Dixit VM: Bcl10 activates the NF-κB pathway through ubiquitination of NEMO. Nature 2004, in press.